ClinicalTrials.gov
ClinicalTrials.gov Menu

Genetic Polymorphysm of Cholesterol 24 S Hydroxylase in Patients With Glaucoma and AMD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00629044
Recruitment Status : Completed
First Posted : March 5, 2008
Last Update Posted : March 28, 2011
Sponsor:
Information provided by:
Centre Hospitalier Universitaire Dijon

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The aim of this study is to assess the implicitement of the cholesterol 24 S hydroxylase gene and the 24 S hydroxycholesterol in glaucoma and in age related macular degeneration.

Condition or disease Intervention/treatment Phase
Glaucoma Biological: Assessing the blood level of cholesterol 24 S Hydroxylase Biological: Assessing the blood level of cholesterol 24 S hydroxylase Biological: assessing the blood level of cholesterol 24 S hydroxylase Not Applicable

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 320 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: Etude du Polymorphysme génétique de la cholestérol 24S Hydroxylase et Des Teneurs en 24S hydroxycholestérol Chez Des Patients Atteints de Glaucome ou de dégénérescence Maculaire liée à l'âge.
Study Start Date : November 2007
Actual Primary Completion Date : November 2009
Actual Study Completion Date : January 2011

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: G Biological: Assessing the blood level of cholesterol 24 S Hydroxylase
Comparison of venous blood level of Cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma and AMD and in healthy subjects.
Active Comparator: AMD Biological: Assessing the blood level of cholesterol 24 S hydroxylase
Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma, AMD end in healthy subjects
Active Comparator: Healthy subjects Biological: assessing the blood level of cholesterol 24 S hydroxylase
Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with glaucoma, AMD and in healthy subjects


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. To know if cholesterol 24 S hydroxylase and 24 hydroxycholesterol are involve in Glaucoma and AMD [ Time Frame: 2 years ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Patient with Glaucoma
  • Patient with AMD
  • Healthy patient

Exclusion Criteria:

  • All patients who use any treatment in order to maintain in normal value their blood cholesterol
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00629044


Locations
France
Ophthalmology Unit CHU Dijon
Dijon, Burgundy, France, 21000
Sponsors and Collaborators
Centre Hospitalier Universitaire Dijon
Investigators
Principal Investigator: Catherine Creuzot-Gracher, MD, PhD CHU Dijon
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Publications:

Responsible Party: Professor Catherine Creuzot-Garcher, CHU Dijon
ClinicalTrials.gov Identifier: NCT00629044     History of Changes
Other Study ID Numbers: PHRC IR 2006
First Posted: March 5, 2008    Key Record Dates
Last Update Posted: March 28, 2011
Last Verified: August 2009

Additional relevant MeSH terms:
Glaucoma
Ocular Hypertension
Eye Diseases